AssetMark Inc’s Rigel Pharmaceuticals RIGL Stock Holding History

AssetMark Inc’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$48	Buy	+1	New	+$43	﹤0.01%	3719

Other funds holding RIGL

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

SummerHaven Investment Management Stamford, Connecticut $179M AUM 57.61% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

AssetMark Inc's RIGL Position: Q3 2026 in Review

AssetMark Inc opened a new position in Rigel Pharmaceuticals (RIGL) in Q3 2026: 1 share worth $48. The stake represents ﹤0.01% of the portfolio and ranks #3719 among its holdings.

45 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

AssetMark Inc held 1 share of Rigel Pharmaceuticals worth $48 as of Q3 2026.
Rigel Pharmaceuticals was a new AssetMark Inc position in Q3 2026.
Rigel Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3719 holding.
45 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.